Home
 /
Papers
 /
Cancer Biology
 /
Mechanoimmunological Control of Metastatic Site Selection
Preprint
Open access
V1
Top 1% · Validated by QED

Mechanoimmunological Control of Metastatic Site Selection

Yassmin A. Elbanna, Maria Tello-Lafoz, Aliya Holland +16 more
May 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.05.10.653256
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Cancer Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that tissue rigidity drives cancer cell stiffening and immune sensitization through Osteopontin, this work overturns biochemical-only models of metastatic tropism and reveals a mechanoimmunological logic governing where—and why—metastases take hold.

QED claims analysis

Summary

Cancer cells undergo mechanoreciprocal stiffening in rigid metastatic microenvironments like bone, which sensitizes them to cytotoxic lymphocyte-mediated destruction through mechanosurveillance, creating an Osteopontin-dependent mechanoimmunological mechanism that dictates metastatic site selection by preferentially suppressing colonization of rigid tissues in immunocompetent hosts.

See full analysis
Main Claim 1 –

Cancer cells stiffen mechanoreciprocally in rigid environments

Main Claim 2 –

Rigidity sensitizes cancer cells to CTL and NK killing

Main Claim 3 –

Cytotoxic lymphocytes preferentially suppress bone metastasis over lung

Supporting evidence

  • NK cells mediate bone metastasis suppression by cytotoxicity
  • Rigidity alone enhances cytotoxic lymphocyte surveillance in vivo
  • Bone-preferential immune suppression extends across cancers and lymphocytes
Main Claim 4 –

MTC stiffness reflects environmental rigidity and immune selection in vivo

Supporting evidence

  • Osteopontin is upregulated in bone metastases in rigid environments
  • Osteopontin enables in vivo immune selection against stiffer cells

Abstract

Cancer cells alter their mechanical properties in response to the rigidity of their environment. Here, we explored the implications of this environmental mechanosensing for anti-tumor immunosurveillance using single cell biophysical profiling and metastasis models. Cancer cells stiffened in more rigid environments, a biophysical change that sensitized them to cytotoxic lymphocytes. In immunodeficient mice, this behavior manifested in the outgrowth of stiffer metastatic cells in the rigid bone than in the soft lung, while in immunocompetent hosts, it led to preferential elimination of stiffer cancer cells and suppression of bone metastasis. Environmentally-induced cell stiffening and immune sensitization both required Osteopontin, a secreted glycoprotein that is upregulated during bone colonization. Analysis of patient metastases spanning mechanically distinct tissues revealed associations between environmental rigidity, immune infiltration, and cancer cell stiffness consistent with mechanically driven immunosurveillance. These results demonstrate how environmental mechanosensing modulates anti-tumor immunity and suggest a mechanoimmunological basis for metastatic site selection.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?